TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. -. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. -. Q. AU - Wang, C. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. AU - Vergnenegre, A. AU - Massuti, B. AU - Felip, E. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Wu, Y. L. AU - Zhou, C. AU - Hu, C. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - JOUR AU - Sun, W. AU - Yuan, X. AU - Tian, Y. AU - Wu, H. AU - Xu, H. AU - Hu, G. PY - 2015 DA - 2015// TI - Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0193-6 DO - 10.1186/s13045-015-0193-6 ID - Sun2015 ER - TY - JOUR AU - Kimura, H. AU - Suminoe, M. AU - Kasahara, K. AU - Sone, T. AU - Araya, T. AU - Tamori, S. PY - 2007 DA - 2007// TI - Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6603949 DO - 10.1038/sj.bjc.6603949 ID - Kimura2007 ER - TY - JOUR AU - Douillard, J. Y. AU - Ostoros, G. AU - Cobo, M. AU - Ciuleanu, T. AU - Cole, R. AU - McWalter, G. PY - 2014 DA - 2014// TI - Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000263 DO - 10.1097/JTO.0000000000000263 ID - Douillard2014 ER - TY - JOUR AU - Couraud, S. AU - Vaca-Paniagua, F. AU - Villar, S. AU - Oliver, J. AU - Schuster, T. AU - Blanche, H. PY - 2014 DA - 2014// TI - Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002 JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3063 DO - 10.1158/1078-0432.CCR-13-3063 ID - Couraud2014 ER - TY - STD TI - Iressa: EPAR - Product Information. European Medicines Agency website. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf. Accessed 23 Jun 2016. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf ID - ref11 ER - TY - STD TI - IRESSA China prescriber information, updated on Feb, 2015, AstraZeneca. ID - ref12 ER - TY - JOUR AU - Sacher, A. G. AU - Oxnard, G. R. AU - Mach, S. L. AU - Melissa, M. M. AU - Jackman, D. M. AU - Janne, P. A. PY - 2014 DA - 2014// TI - Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA) JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.7804 DO - 10.1200/JCO.2013.52.7804 ID - Sacher2014 ER - TY - JOUR AU - Wang, J. AU - Yang, X. AU - Zhuo, M. AU - Ye, X. AU - Bai, H. AU - Wang, Z. PY - 2015 DA - 2015// TI - Quantification of mutant alleles in circulating tumor DNA from advanced non-small cell lung cancer JO - J Thorac Oncol VL - 10 ID - Wang2015 ER - TY - JOUR AU - Marchetti, A. AU - Palma, J. F. AU - Felicioni, L. AU - Pas, T. M. AU - Chiari, R. AU - Grammastro, M. PY - 2015 DA - 2015// TI - Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000643 DO - 10.1097/JTO.0000000000000643 ID - Marchetti2015 ER - TY - JOUR AU - Mok, T. AU - Wu, Y. L. AU - Lee, J. S. AU - Yu, C. J. AU - Sriuranpong, V. AU - Sandoval-Tan, J. PY - 2015 DA - 2015// TI - Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2594 DO - 10.1158/1078-0432.CCR-14-2594 ID - Mok2015 ER - TY - JOUR AU - Zhou, Q. AU - Zhang, X. C. AU - Chen, Z. H. AU - Yin, X. L. AU - Yang, J. J. AU - Xu, C. R. PY - 2011 DA - 2011// TI - Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.3757 DO - 10.1200/JCO.2010.33.3757 ID - Zhou2011 ER - TY - JOUR AU - Yang, J. C. AU - Wu, Y. L. AU - Schuler, M. AU - Sebastian, M. AU - Popat, S. AU - Yamamoto, N. PY - 2015 DA - 2015// TI - Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71173-8 DO - 10.1016/S1470-2045(14)71173-8 ID - Yang2015 ER - TY - JOUR AU - Zhang, Y. AU - Sheng, J. AU - Kang, S. AU - Fang, W. AU - Yan, Y. AU - Hu, Z. PY - 2014 DA - 2014// TI - Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0107161 DO - 10.1371/journal.pone.0107161 ID - Zhang2014 ER - TY - JOUR AU - Wang, S. AU - Su, X. AU - Bai, H. AU - Zhao, J. AU - Duan, J. AU - An, T. PY - 2015 DA - 2015// TI - Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0210-9 DO - 10.1186/s13045-015-0210-9 ID - Wang2015 ER - TY - JOUR AU - Diaz, L. A. AU - Bardelli, A. PY - 2014 DA - 2014// TI - Liquid biopsies: genotyping circulating tumor DNA JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2012.45.2011 DO - 10.1200/JCO.2012.45.2011 ID - Diaz2014 ER - TY - JOUR AU - Roma, C. AU - Esposito, C. AU - Rachiglio, A. M. AU - Pasquale, R. AU - Iannaccone, A. AU - Chicchinelli, N. PY - 2013 DA - 2013// TI - Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology JO - Biomed Res Int VL - 2013 UR - https://doi.org/10.1155/2013/385087 DO - 10.1155/2013/385087 ID - Roma2013 ER - TY - JOUR AU - Angulo, B. AU - Conde, E. AU - Suarez-Gauthier, A. AU - Plaza, C. AU - Martinez, R. AU - Redondo, P. PY - 2012 DA - 2012// TI - A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0043842 DO - 10.1371/journal.pone.0043842 ID - Angulo2012 ER - TY - JOUR AU - Thress, K. S. AU - Brant, R. AU - Carr, T. H. AU - Dearden, S. AU - Jenkins, S. AU - Brown, H. PY - 2015 DA - 2015// TI - EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291 JO - Lung Cancer VL - 90 UR - https://doi.org/10.1016/j.lungcan.2015.10.004 DO - 10.1016/j.lungcan.2015.10.004 ID - Thress2015 ER - TY - JOUR AU - Wang, S. AU - Cang, S. AU - Liu, D. PY - 2016 DA - 2016// TI - Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0268-z DO - 10.1186/s13045-016-0268-z ID - Wang2016 ER -